Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates|
|Abstract:||A process for the long term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.|
|Inventor(s):||Meier; Albert H. (Baton Rouge, LA), Cincotta; Anthony H. (Baton Rouge, LA)|
|Assignee:||Louisiana State University and Agricultural and Mechanical College (Baton Rouge, LA)|
|Filing Date:||May 26, 1995|
|Claims:||1. A method for modifying an aberrant glucose metabolism in a human in need of treatment comprising administering prolactin into the blood stream of said human at a predetermined time within the daily interval at which the prolactin level in the bloodstream of a lean insulin-sensitive human reaches its peak value, thereby achieving at least one of the following: reduction of hyperinsulinemia decrease in insulin resistance, and reduced plasma insulin levels. |
2. The method of claim 1 wherein the modification persists after cessation of said prolactin administration.
3. The method of claim 1 further comprising administering a glucocorticosteroid to said human.
4. The method of claim 3 wherein said glucocorticosteroid is administered daily at a second predetermined time of day, said second time being within the daily time interval at which the glucocorticosteroid level of a lean insulin-sensitive human reaches its peak value.
5. The method of claim 1 wherein prolactin is administered once a day at dosage levels ranging from about 175 micrograms to about 2000 micrograms, per pound of body weight.
6. The method of claim 4 wherein the prolactin is administered at dosage levels ranging from about 175 micrograms to about 2000 micrograms per pound body weight, and glucocorticosteroid is administered at dosage levels ranging from about 175 micrograms to about 2000 micrograms, per pound body weight.
7. The method of claim 4 wherein the glucocorticosteroid is cortisol.
8. The method of claim 1 wherein the prolactin is administered daily at said predetermined time.